Status:
COMPLETED
Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
Lead Sponsor:
Guerbet
Conditions:
Type 2 Diabetes Mellitus
Coronary Atherosclerosis
Eligibility:
All Genders
50-75 years
Phase:
PHASE4
Brief Summary
The study aimed to prospectively investigate the prevalence of myocardial scar on Dotarem-enhanced Cardiovascular Magnetic Resonance Imaging (MRI) in asymptomatic patients with type-2 Diabetes Mellitu...
Detailed Description
Patients underwent a cardiac MRI examination with Dotarem within 60 days after screening visit. The myocardial CCTA examination with Xenetix 350 was performed within 1 to 30 days (but no sooner than 2...
Eligibility Criteria
Inclusion
- Patient with onset of type 2 diabetes occurred at age 30 years or older
- Patient between the ages of 50 and 75 years at enrolment time
- Patient with at least two identified cardiac risk factors who will undergo a CMR and a CCTA examinations to evaluate his/her coronary and cardiac status
Exclusion
- Patient with angina pectoris or chest discomfort
- Patient with stress test or invasive coronary angiography within the prior 3 years
- Patient with history of myocardial infarction, overt non compensated heart failure, or coronary revascularization
- Patient with hemodynamic instability.
- Patient with a contraindication or intolerance to Beta-Blocker administration
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
351 Patients enrolled
Trial Details
Trial ID
NCT01254552
Start Date
August 1 2010
End Date
October 1 2016
Last Update
May 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea